Investigational drug treatment for pancreatic cancer

Trial ID:
IRB-16-6853
Darren Sigal, M.D.
This study combines an investigational drug with chemotherapy and radiation therapy for treatment of non-operable pancreatic cancer that has not metastasized (spread)

Inclusion Criteria

  • Have not received any prior treatment for pancreatic cancer
  • Meet all other eligibility criteria

Exclusion Criteria

  • Be a candidate for surgical removal of the tumor
  • Have a history of stroke, TIA or carotid artery disease
  • Be pregnant or breastfeeding
  • Have a history of HIV, hepatitis B or hepatitis C

Additional Info

  • This study combines an investigational medication, PEGPH20, with gemcitabine and daily radiation therapy for 6 – 7 weeks. The combination of gemcitabine and daily radiation therapy are already being used to treat pancreatic cancer that has not metastasized (spread) to other areas of the body

Contact Info:

  • Shannon Cyhan
  • cyhan.shannon@scrippshealth.org